Abstract
CTLA-4 (Cytotoxic T Lymphocyte Antigen-4) is an immune regulator molecule that is expressed on a variety of immune cells, including CD4+ and CD8+ T cells. After realizing the significance of this regulator molecule, researchers began to concentrate on its activation or inhibition in cancer. Even though there have been some studies on organ transplantation and autoimmunity, the role of the CTLA-4 molecule in renal transplantation has not been demonstrated. The goal of this study was to see how CTLA-4 gene expression and serum sCTLA-4 levels affected renal transplant patients. Peripheral blood samples were collected before and 1–3 months after renal transplantation from 29 recipients. CD8+ T lymphocytes were separated using magnetic beads and purity of the cells controlled by Flow cytometry. CTLA-4 mRNA levels were determined by Real-Time PCR while serum sCTLA-4 levels were assessed by ELISA. 55% of the patient had decreased level of CTLA-4 mRNA after transplantation when compared to pre-transplantation levels. Moreover 61% of the patient had lower serum sCTLA-4 levels after transplantation. sCTLA-4 levels were decreased 11% of the patients with rejection episode after transplantation when compared to stabile patients (5%). Kidney rejection is a complicated process influenced by numerous unknown factors. Several parameters should be evaluated together to precise rejection episodes or graft dysfunctions. Further research focused on the other immune checkpoint regulator molecules could give an opportunity to have an idea about the effect of these molecules on renal transplantation.
Similar content being viewed by others
References
Crepeau RL, Ford ML (2017) Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity. Expert Opin Biol Ther 17(8):1001–1012
Eikmans M, Gielis EM, Ledeganck KJ, Yang J, Abramowicz D, Claas FFJ (2018) Non-invasive biomarkers of acute rejection in kidney transplantation: novel targets and strategies. Front Med (lausanne) 5:358
Esposito P, Grosjean F, Rampino T et al (2014) Costimulatory pathways in kidney transplantation: pathogenetic role, clinical significance and new therapeutic opportunities. Int Rev Immunol 33(3):212–233
Ghoneim HE, Zamora AE, Thomas PG, Youngblood BA (2016) Cell-intrinsic barriers of T cell-based immunotherapy. Trends Mol Med 22(12):1000–1011
Grywalska E, Smarz-Widelska I, Mertowski S et al (2019) CTLA-4 expression inversely correlates with kidney function and serum immunoglobulin concentration in patients with primary glomerulonephritides. Arch Immunol Ther Exp (warsz) 67(5):335–349
Han FL, Liang F, Jiang TC, Liu M (2017) Increased expression of CXCR5 and CXCL13 in mice with experimental autoimmune myocarditis. Eur Rev Med Pharmacol Sci 21(8):1860–1867
Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B (2020) CTLA-4: from mechanism to autoimmune therapy. Int Immunopharmacol 80:10622
Jeong HJ (2020) Diagnosis of renal transplant rejection: Banff classification and beyond. Kidney Res Clin Pract 39(1):17–31
Karahan HI, Soyöz M, Pehlivan M et al (2019) Assessment of interleukin 2 cytokine expression levels after renal transplantation. Transplant Proc 51(4):1074–1077
Kittai AS, Oldham H, Cetnar J, Taylor M (2017) Immune checkpoint inhibitors in organ transplant patients. J Immunother 40:277–281
Kosmaczewska A, Magott-Procelewska M, Frydecka I et al (2006) CD40L, CD28, and CTLA-4 expression on CD4+ T cells in kidney graft recipients: a relationship with post-transplantation clinical course. Transpl Immunol 16(1):32–40
Li B, Hartono C, Ding R et al (2001) Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 344(13):947–954
Mitsuiki N, Schwab C, Grimbacher B (2019) What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev 287(1):33–49
Oyewole-Said D, Konduri V, Vazquez-Perez J, Weldon SA, Levitt JM, Decker WK (2020) Beyond T-cells: functional characterization of CTLA-4 expression in immune and non-immune cell types. Front Immunol 11:608024
Rudd CE, Taylor A, Schneider H (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229(1):12–26
Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR, Elkord E (2018) DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics 10:78
Shahbaz SK, Barabadi M, Ahmadpour P et al (2019) Sequential monitoring of TIM-3 mRNA expression in blood and urine samples of renal transplant recipients. Transpl Immunol 54:9–16
Simon T, Opelz G, Wiesel M, Ott RC, Susal C (2003) Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant 3(9):1121–1127
Vasconcellos LM, Schachter AD, Zheng XX et al (1998) Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 66(5):562–566
Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20:651–668
West SM, Deng XA (2019) Considering B7-CD28 as a family through sequence and structure. Exp Biol Med (maywood) 244(17):1577–1583
Funding
This project was supported by Izmir Katip Celebi University Scientific Research Foundation (Project No: 2019-TDR-SABE-0006).
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. BÇA, MS and MP designed, coordinated the study, analyzed the experiment and wrote the paper. TKA performed patient follow-up and revised the paper. ET, MT and HİKÇ follow-up the patients, analyzed the clinical situations of the patients. İP analyzed the results and revised the paper. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors have no relevant financial or non-financial interests to disclose.
Ethical Approval
Ethics committee approval was received for this study from Health Science University İzmir Tepecik Training and Research Hospital Clinical Research Ethical Committee with the number of 22.02.2019/03.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Çerçi Alkaç, B., Soyöz, M., Pehlivan, M. et al. Assessment of CTLA-4 Gene Expression Levels on CD8+ T Cells in Renal Transplant Patients and Relation with Serum sCTLA-4 Levels. Biochem Genet (2024). https://doi.org/10.1007/s10528-024-10723-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10528-024-10723-7